Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apellis Pharmaceuticals
Biotech
Ocugen update charts course for rivalry with Apellis, Astellas
Ocugen reported phase 2 data on its eye disease gene therapy, providing evidence that the candidate may outperform drugs from Apellis and Astellas.
Nick Paul Taylor
Jan 15, 2026 9:22am
Apellis COO stepping down to take first CEO job—Chutes & Ladders
Jan 17, 2025 8:30am
Bausch + Lomb pens $485M-plus biobucks pact with City Tx
Jan 10, 2025 6:37am
Another Biogen exec hitches ride to Voyager —Chutes & Ladders
Mar 15, 2024 9:30am
Apellis lays off 25%, trims pipeline to free up cash for Syfovre
Aug 29, 2023 10:15am
Annexon eye disease med failed phase 2 goal—the CEO is thrilled
May 24, 2023 4:01pm
